News | Treatment Planning | March 08, 2019

Mississippi Cancer Center Combines RayStation and TomoTherapy for Prostate Cancer Case

Collaboration marks first case in U.S. combining the two technologies

Mississippi Cancer Center Combines RayStation and TomoTherapy for Prostate Cancer Case

March 8, 2019 — Anderson Regional Cancer Center in Meridian, Miss., has treated its first patient using the combination of RaySearch's treatment planning system (TPS) RayStation and Accuray's TomoTherapy Treatment Delivery System. This is the first-ever treatment in the U.S. using the two technologies in combination.

Anderson Regional Cancer Center first began using RayStation in 2013 with its conventional linear accelerators, which provided significant benefits for workflow and patient treatments. The center then added the TomoTherapy System for radiation treatment. Anderson has worked closely with RaySearch and Accuray to join the technologies and is now using RayStation for all radiation treatment planning, which is providing substantial gains in efficiency. Additionally, the high-precision treatment delivery provided by the TomoTherapy System will help ensure the best possible radiation treatments for patients.

The first treatment combining RayStation and TomoTherapy System at Anderson Regional Cancer Center was successfully administered to treat a prostate cancer patient. Moving forward, the center plans to use this combination of TPS and radiation treatment delivery system to also treat cancers of the breast, lung, and head and neck.

Scott Anderson, M.D., radiation oncologist and medical director at Anderson Regional Cancer Center, said: "We have watched these progressive companies develop through the years, and we are all very excited to be at this juncture. Integrating RayStation planning for multiple accelerator platforms enables us to fully embrace the TomoTherapy System's advantages. The future of our patients certainly looks brighter with the ability to unify these developments."

Paul King, chief medical physicist at Anderson Regional Cancer Center, said: "This clinical launch is very significant. It is a big step in an evolving story that has just begun, considering the quality of RayStation's design as it is today, as well as the intensity and direction of its ongoing development."

For more information: www.raysearchlabs.com, www.accuray.com

Related Content

An example of the MRI scans showing long-term and short-term survival indications. #MRI

An example of the MRI scans showing long-term and short-term survival indications. Image courtesy of Case Western Reserve University

News | Magnetic Resonance Imaging (MRI) | February 21, 2020
February 21, 2020 — ...
Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure

Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure. This picture shows a circle of hydrogel that was irradiated on the left half, which is slightly pink; whereas the right half of the gel is not irradiated and remains colorless.

News | Radiation Therapy | February 18, 2020
February 18, 2020 — More than half of all cancer patients undergo radiation therapy and the dose is critical.
Nuclear imaging equipment growth in 2020
News | Nuclear Imaging | February 14, 2020
February 14, 2020 — The nuclear imaging equipment
Varian announced it has received FDA 510(k) clearance for its Ethos therapy, an Adaptive Intelligence solution. Ethos therapy is an artificial intelligence (AI)-driven holistic solution that provides an opportunity to transform cancer care.
News | Image Guided Radiation Therapy (IGRT) | February 11, 2020
February 11, 2020 — Varian announced it has received FDA 510(k) c
The radiation therapy market is projected to grow in through 2026

Image courtesy of Accuray

News | Proton Therapy | February 10, 2020
February 10, 2020 — Amid technological advancement, and notable research and development activities, the global ...
SIR President Laura Findeiss, M.D., FSIR

SIR President Laura Findeiss, M.D., FSIR

News | Interventional Radiology | February 09, 2020
February 9, 2020 — For some patients, kidney cancer can be effectively treated without surgery, according to the...
Accuray TomoTherapy total body irradiation
News | Radiation Therapy | February 07, 2020
February 7, 2020 — Accuray Incorporated announced that two new studies demonstrate the benefits of the ...
Purdue University-discovered fluorescent markers to target and illuminate cancer during surgery, has announced the results of a multi-institutional Phase 2 clinical trial in which outcomes were improved for 26 percent of patients undergoing pulmonary resection for non-small-cell lung cancer (NSCLC)

A Purdue discovery being developed by On Target Laboratories Inc., illuminates lung cancer cells on a patient during surgery. The “fluorescent markers” help medical professionals identify and remove cancer cells during surgery and is shown to improve outcomes. The technology is beginning Phase 3 clinical trials. (Photo provided by On Target)

News | Molecular Imaging | February 06, 2020
February 6, 2020 — ...
The luminescent oxygen probe PtG4 is injected during the week of radiation treatment and localizes between the cells of the tumor as illustrated by microscopy

An oxygen map image recovered from a mouse undergoing radiation therapy. The luminescent oxygen probe PtG4 is injected during the week of radiation treatment and localizes between the cells of the tumor as illustrated by microscopy (red). Image courtesy of Brian Pogue, PhD

News | Radiation Therapy | February 03, 2020
February 3, 2020 — Oxygen in cancer tumors is known to be a major factor that helps radiation therapy be successful.